SCHEMBL3771013

SCHEMBL3771013

Cc1nc2c(Cl)ccc(CC(=O)O)c2c(C)c1Cc1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.39
PTGDR2 Q9Y5Y4 6/20 0.38
ENPP2 Q13822 1/20 0.37
KDM4E B2RXH2 2/20 0.37
LMNA P02545 2/20 0.36
PLA2G2A P14555 1/20 0.36
KMT2A Q03164 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
KCNH2 Q12809 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
CXCL8 P10145 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3777522 0.88 PTGDR2 (0.45) PTGDR2
SCHEMBL3781729 0.88 ALDH1A1 (0.41) KDM4ELMNAPLA2G2AKMT2ANPSR1
SCHEMBL3771036 0.83 LMNA (0.38) EGLN1PTGDR2ENPP2LMNAPLA2G2A
SCHEMBL3779168 0.81 TDP1 (0.45) EGLN1PTGDR2
SCHEMBL3775557 0.80 KMT2A (0.40) EGLN1ENPP2KDM4EKMT2ANPSR1
SCHEMBL3777107 0.79 KDM4E (0.46) EGLN1PTGDR2ENPP2KDM4ELMNA
SCHEMBL3788385 0.79 PTGDR2 (0.43) PTGDR2CYP2C9
SCHEMBL27826435 0.78 KDM4E (0.38) EGLN1ENPP2KDM4ELMNAPLA2G2A
SCHEMBL3784536 0.78 EGLN1 (0.39) EGLN1PTGDR2KDM4ELMNAALDH1A1
SCHEMBL3780495 0.78 PTGDR2 (0.48) EGLN1PTGDR2ENPP2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
CN-101316591-B Quinoline compound and pharmaceutical application thereof ARGENTA ORAL THERAPEUTICS LTD. (GB) 2012-02-01 CN disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 EGLN1 3003/4885PTGDR2 146/4885ENPP2 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.